Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
CJC-1295 + Ipamorelin — complete Encore Bio Labs reference vialMATERIAL / 05

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

CJC-1295 + Ipamorelin

Hormone-release research has more than one starting point. This pairing brings together CJC-1295, studied through the GHRH pathway, and Ipamorelin, investigated through a different receptor pathway. Two components with distinct scientific backgrounds for a closer look at how hormone-release signals begin.

CAS
863288-34-0 / 170851-70-4

Formats & reference pricing

USD
Listed formatReference price
5 mg + 5 mg$65 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

Two names, two molecular identities

CJC-1295 and ipamorelin have separate chemical records; combining their names does not create one peptide sequence. Ipamorelin's reference structure contains five amino-acid residues, including modified residues. For this combination, the exact CJC form and each component's identity must be distinguished from the blend name and nominal quantities.

Named components
CJC-1295 + ipamorelin
Ipamorelin reference
Five amino-acid residues; exact CJC form pending

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
CJC-1295 + Ipamorelin
CAS
863288-34-0 / 170851-70-4
Listed formats
5 mg + 5 mg
Reference price range
$65 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Regulatory context

Regulatory & safety notes.

FDA’s public compounding materials can provide regulatory safety context. They do not verify a current Encore Bio Labs lot.

FDA PUBLIC RECORD · REVIEWED OCT 2026CJC-1295 + Ipamorelin

FDA compounding record · CJC-1295 + Ipamorelin

FDA describes potential immunogenicity and characterization concerns for CJC-1295 and limited clinical data, and separately describes immunogenicity, characterization, and safety-data concerns for ipamorelin acetate. The FDA record evaluates the substances separately; it does not establish the composition, safety, or suitability of this catalog combination.

Public FDA safety-context information does not establish approval, equivalence to an approved product, or current-lot quality for either component or the combination.

FDA record type
Human drug compounding safety context
Human-use guidance
Not provided

External public record

FDA · Bulk drug substances and potential safety risks

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for CJC-1295 + Ipamorelin in this catalog.

Encore documentary summary · not a laboratory-issued COA

Report availability
4 related reports located
Formats & scope
Related reports specify CJC-1295 without DAC with Ipamorelin. A newly supplied report names 10 mg + 10 mg; the catalog lists 5 mg + 5 mg.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Exact chemical form, catalog identifier and component quantities require reconciliation. The new privacy-redacted copy remains internal because its format differs; the names alone do not establish equivalence.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Report review pending

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Copy preparation
4 source files in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Release review pending. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
No website copy released. No download is available for this product.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Select individual reports for release after reviewing remaining privacy exposure, sample scope and discrepancies. A prepared review packet is not a cleared public copy.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which CJC-1295 + Ipamorelin formats and reference prices are listed?

5 mg + 5 mg: $65 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the CJC-1295 + Ipamorelin reports?

Report review pending. The Documentation section on this page lists the reviewed source status and outstanding items for this material. No public PDF is available for this product; an unreleased or missing document is not a certificate of current inventory.

03Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

04How should research suitability be assessed?

Qualified personnel should evaluate material identity, lot-specific records, institutional requirements, and study design. Report review pending. Independent inventory review remains pending, and no product-specific SDS was located in the reviewed set. This catalog provides no personal-use or preparation guidance.

Continue the collection

Next in the catalog.

View all materials